Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$176.4MCash on Hand
123.6mo Cash Runway
Follow BNTC by emailGet an email when BNTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BNTC, unsubscribe in one click. Privacy
📣 What BNTC Says Is Next
mid-2027 · “BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-2027”
Company press release, Nov 13, 2026 · SEC filing
mid-2027 · “Patient enrollment is planned to begin in mid-2027.”
Company press release, Oct 5, 2026 · SEC filing
1Q 2027 · “Final pivotal study design expected to be confirmed in 1Q 2027”
Company press release, Oct 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Benitec reported a $12.9 million net loss for the quarter ended September 30, 2026, with R&D expenses of $8.6 million and $176.5 million in cash. It also plans to change its fiscal year-end from June 30 to December 31. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
Clinical trial Reported positive interim Phase 1b/2a results for high dose BB-301 in OPMD-related dysphagia, with 100% of treated patients across both doses meeting formal responder criteria. Cohort 2 (high dose) showed 100% vs. 67% response for throat emptying and 67% vs. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Shareholder vote Benitec Biopharma will hold its 2026 annual meeting virtually on December 3, 2026, at 1:00 p.m. Pacific Time. Stockholders will vote on electing three Class I directors, ratifying the independent accounting firm for fiscal 2027, and a non-binding say-on-pay vote. Form DEF 14A · SEC filing
Oct 5, 2026 ·
Regulatory Following Type C meeting feedback, FDA requested additional data including from the OPMD Natural History Study for a single-arm pivotal study of BB-301. Final pivotal design expected to be confirmed in 1Q 2027, with enrollment planned for mid-2027. Form 8-K · SEC filing · Press release
Sep 30, 2026 ·
Benitec Biopharma engaged Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027. EY completed client acceptance on September 28, 2026, and the engagement letter was executed September 29, 2026. Form 8-K · SEC filing
Sep 24, 2026 ·
Leadership Audit committee dismissed Baker Tilly US, LLP on September 18, 2026 and appointed Ernst & Young LLP as auditor for the fiscal year ending June 30, 2027, subject to EY's client acceptance. Baker Tilly's prior reports had no adverse opinion or going-concern qualification. Form 8-K · SEC filing
Sep 14, 2026 ·
Earnings Reported a net loss of $45.5 million, or $0.98 per share, for fiscal year ended June 30, 2026, versus $37.9 million for the prior year, with $180.0 million in cash. Interim BB-301 data will be presented at ESGCT on October 27-30, 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2030 · Phase 1/2 · Recruiting · A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BNTC holds $176.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.3M/quarter from operations,
an estimated runway of 123.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 124 months
ATM program on file since Sep 2025 +15
Shelf registration (S-3, Sep 2026) +10
Recent financing filings on SEC EDGAR:
Sep 14, 2026 · Shelf registration, up to $200M · S-3
Nov 7, 2025 · Registered direct / best-efforts offering · 424B5
Nov 5, 2025 · Registered direct / best-efforts offering · 424B5
Sep 22, 2025 · Shelf registration with ATM program, up to $125M · S-3
Mar 26, 2025 · Registered direct / best-efforts offering · 424B5
Nov 1, 2024 · Shelf registration with ATM program, up to $125M · S-3
Share count 36,119,043 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BNTC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BNTC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.